- Report
- October 2024
- 191 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- February 2025
- 284 Pages
Global
From €5205EUR$5,450USD£4,353GBP
- Report
- July 2024
- 175 Pages
Global
From €4775EUR$5,000USD£3,993GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1910EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1194EUR$1,250USD£998GBP
- Report
- May 2024
- 181 Pages
Global
From €4298EUR$4,500USD£3,594GBP
- Report
- May 2024
- 133 Pages
Global
From €6207EUR$6,499USD£5,190GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7593EUR$7,950USD£6,349GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- January 2022
- 60 Pages
Global
From €3772EUR$3,950USD£3,155GBP
- Report
- March 2023
- 147 Pages
Global
From €4726EUR$4,949USD£3,953GBP
- Report
- March 2024
- 200 Pages
Global
From €3963EUR$4,150USD£3,314GBP
- Report
- February 2024
- 112 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- October 2023
- 180 Pages
Global
From €4298EUR$4,500USD£3,594GBP
- Report
- August 2023
- 110 Pages
Global
From €3500EUR$3,926USD£3,029GBP
- Report
- December 2022
- 30 Pages
Global
From €1910EUR$2,000USD£1,597GBP

Tinea Pedis, commonly known as athlete's foot, is a fungal infection of the skin that affects the feet. It is caused by a variety of fungi, including Trichophyton, Epidermophyton, and Microsporum. Treatment for tinea pedis typically involves the use of antifungal drugs, such as terbinafine, itraconazole, and clotrimazole. These drugs are available in both topical and oral forms, and are used to treat the infection and prevent its recurrence.
The tinea pedis drug market is a segment of the infectious diseases drugs market. It is composed of a variety of antifungal drugs used to treat tinea pedis. These drugs are available in both prescription and over-the-counter forms, and are used to treat the infection and prevent its recurrence.
Some companies in the tinea pedis drug market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Bayer. Show Less Read more